evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,139 questions · 1,173 findings · 89 reviews · Neuromuscular

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 302 · 25.7%GRADE not reported 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%

Intervention not reported

Number with ≥ 50% pain relief at 12 weeks or less · patients with pain in major depressive disorder

The intervention probably leads to higher number with ≥ 50% pain relief at 12 weeks or less (moderate certainty).

1 finding from 1 review

Intervention not reported

Number with ≥ 30% pain relief at 12 weeks or less · patients with pain in major depressive disorder

The intervention may leads to higher number with ≥ 30% pain relief at 12 weeks or less (low certainty).

1 finding from 1 review

Intervention not reported

Mean improvement in Patient Reported Global Impression of Change at 12 weeks or less · patients with pain in major depressive disorder

The review found no eligible studies for this question.

1 finding from 1 review

Intervention not reported

Mean improvement in pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert score Scale from: 0 to 10 · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy
1 finding from 1 review

Intervention not reported

Number of patients with ≥ 30% improvement in pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert scale · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

The intervention probably leads to higher number of patients with ≥ 30% improvement in pain at 12 weeks or… (moderate certainty).

1 finding from 1 review

Intervention not reported

Mean improvement in Patient Reported Global Impression of Change at 12 weeks or less Duloxetine 60 mg daily VAS Scale from: 0 to 10 · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy
1 finding from 1 review

Intervention not reported

Adverse event leading to cessation All neuropathic pain indications Duloxetine 60 mg daily · patients with painful neuropathy or chronic pain from diabetic peripheral neuropathy

The intervention may leads to higher adverse event leading to cessation All neuropathic pain indications… (low certainty).

1 finding from 1 review

Intervention not reported

Number with ≥ 50% improvement of pain at 12 weeks or less Duloxetine 60 mg daily 11‐point Likert scale · patients with the chronic pain of fibromyalgia

The intervention may leads to higher number with ≥ 50% improvement of pain at 12 weeks or less Duloxetine… (low certainty).

1 finding from 1 review

Intervention not reported

Number with ≥ 30% improvement of pain at 12 weeks or less Duloxetine 60 mg daily · patients with the chronic pain of fibromyalgia

The intervention may leads to higher number with ≥ 30% improvement of pain at 12 weeks or less Duloxetine… (low certainty).

1 finding from 1 review

Intervention not reported

Mean improvement in the Patient Reported Global Impression of Change at completion of trial Duloxetine 60 mg daily VAS Scale from: 0 to 10 · patients with the chronic pain of fibromyalgia
1 finding from 1 review

Intervention not reported

Mean improvement in pain at 12 weeks or less Duloxetine 120 mg daily LikertScale from: 0 to 10 · patients with the chronic pain of fibromyalgia
1 finding from 1 review

Amantadine vs placebo

Reduction in fatigue · people with fatigue in Guillain‐Barré syndrome

Amantadine showed no clear difference in reduction in fatigue of at least 1‐point on the Fatigue Severity… compared with placebo (low certainty).

1 finding from 1 review

Ascorbic acid vs placebo

Serious adverse events · people with fatigue in peripheral neuropathy

Ascorbic acid showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review